Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nathanael Gray, Ph.D.

Co-Author

This page shows the publications co-authored by Nathanael Gray and Sara Buhrlage.
Connection Strength

2.321
  1. Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. ACS Med Chem Lett. 2020 Nov 12; 11(11):2238-2243.
    View in: PubMed
    Score: 0.233
  2. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215.
    View in: PubMed
    Score: 0.189
  3. Discovery of type II inhibitors of TGFß-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 08; 58(1):183-96.
    View in: PubMed
    Score: 0.152
  4. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014 May 16; 9(5):1086-91.
    View in: PubMed
    Score: 0.148
  5. Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. Biochem J. 2014 Jan 01; 457(1):215-25.
    View in: PubMed
    Score: 0.146
  6. Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol. 2013 Feb 21; 20(2):146-59.
    View in: PubMed
    Score: 0.137
  7. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011). Expert Opin Ther Pat. 2012 Dec; 22(12):1415-26.
    View in: PubMed
    Score: 0.134
  8. The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 06 16.
    View in: PubMed
    Score: 0.061
  9. Targeting oncoproteins with a positive selection assay for protein degraders. Sci Adv. 2021 Feb; 7(6).
    View in: PubMed
    Score: 0.060
  10. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. 2020 12 10; 183(6):1714-1731.e10.
    View in: PubMed
    Score: 0.059
  11. Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 Sep; 34(9):2543.
    View in: PubMed
    Score: 0.058
  12. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res. 2020 Aug 10; 37(9):167.
    View in: PubMed
    Score: 0.058
  13. Inhibition of the deubiquitinase USP10 induces degradation of SYK. Br J Cancer. 2020 04; 122(8):1175-1184.
    View in: PubMed
    Score: 0.056
  14. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 01 31; 10(1):12.
    View in: PubMed
    Score: 0.055
  15. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. J Cell Mol Med. 2020 03; 24(5):2968-2980.
    View in: PubMed
    Score: 0.055
  16. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. J Cell Mol Med. 2020 02; 24(3):2145-2156.
    View in: PubMed
    Score: 0.055
  17. Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 02; 34(2):625-629.
    View in: PubMed
    Score: 0.054
  18. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019 11; 187(4):488-501.
    View in: PubMed
    Score: 0.053
  19. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). J Biol Chem. 2019 03 22; 294(12):4511-4519.
    View in: PubMed
    Score: 0.052
  20. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood. 2018 05 03; 131(18):2047-2059.
    View in: PubMed
    Score: 0.049
  21. Crystal structure of human IRAK1. Proc Natl Acad Sci U S A. 2017 12 19; 114(51):13507-13512.
    View in: PubMed
    Score: 0.048
  22. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 2017 06 01; 19(6):774-785.
    View in: PubMed
    Score: 0.046
  23. Leveraging Gas-Phase Fragmentation Pathways for Improved Identification and Selective Detection of Targets Modified by Covalent Probes. Anal Chem. 2016 12 20; 88(24):12248-12254.
    View in: PubMed
    Score: 0.045
  24. Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood. 2016 07 14; 128(2):239-48.
    View in: PubMed
    Score: 0.043
  25. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52.
    View in: PubMed
    Score: 0.043
  26. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017 06; 177(5):808-813.
    View in: PubMed
    Score: 0.043
  27. Inhibiting fungal multidrug resistance by disrupting an activator-Mediator interaction. Nature. 2016 Feb 25; 530(7591):485-9.
    View in: PubMed
    Score: 0.042
  28. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016 Jan; 30(1):173-81.
    View in: PubMed
    Score: 0.040
  29. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Nat Commun. 2014 Aug 27; 5:4763.
    View in: PubMed
    Score: 0.038
  30. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. . 2013 Dec; 12(12):2651-62.
    View in: PubMed
    Score: 0.036
  31. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013 Aug 15; 122(7):1222-32.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.